FDA Archives - Probing Edge

FDA Approves Revumenib as Therapy for Relapsed or Refractory AML

Pune, India | October 27, 2025 The U.S. Food and Drug Administration (FDA) recently approved revumenib, an innovative oral menin inhibitor, to treat relapsed or

FDA Grants Approval to BLENREP for Treating Multiple Myeloma

Pune, India | October 24, 2025 The recent U.S. Food and Drug Administration (FDA) approval of Blenrep (belantamab mafodotin-blmf) for adults with relapsed or refractory

Zynex Receives FDA Approval for TensWave, Expands Drug-Free Pain Therapy

By Mursalin Pathan – Content Writer Pune, India | October 20, 2025 Zynex, a prominent developer of non-invasive medical technologies, has received clearance from the

FDA Approves Combo Therapy to Prolong Survival in Advanced Lung Cancer

Pune, India | October 07, 2025 The U.S. Food and Drug Administration (FDA) has officially approved a new maintenance therapy for adults with extensive-stage small

FDA Expands Evkeeza Approval to Children 1+ with Rare Cholesterol Disorder

Pune, India | October 03, 2025 The U.S. Food and Drug Administration (FDA) has approved Evkeeza® (evinacumab‑dgnb) for children as young as one year diagnosed

FDA Rejects Regeneron’s Request to Expand EYLEA HD® Label

Pune, India | August 26, 2025 Regeneron Pharmaceuticals received a Complete Response Letter (CRL) from the FDA that denied its request to expand the EYLEA HD®

FDA Grants Accelerated Approval to Avutometinib–Defactinib Combo for KRAS-Mutant Ovarian Cancer

Pune, India | August 21, 2025 The U.S. Food and Drug Administration (FDA) has granted accelerated approval for a new targeted treatment that combines avutometinib

Probing Edge

BREAKING NEWS

Tag: FDA

FDA Approves Revumenib as Therapy for Relapsed or Refractory AML

FDA Grants Approval to BLENREP for Treating Multiple Myeloma

Zynex Receives FDA Approval for TensWave, Expands Drug-Free Pain Therapy

FDA Approves Combo Therapy to Prolong Survival in Advanced Lung Cancer

FDA Expands Evkeeza Approval to Children 1+ with Rare Cholesterol Disorder

FDA Rejects Regeneron’s Request to Expand EYLEA HD® Label

FDA Grants Accelerated Approval to Avutometinib–Defactinib Combo for KRAS-Mutant Ovarian Cancer